These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30408555)

  • 1. Boosting RNAi therapy for orthotopic glioblastoma with nontoxic brain-targeting chimaeric polymersomes.
    Shi Y; Jiang Y; Cao J; Yang W; Zhang J; Meng F; Zhong Z
    J Control Release; 2018 Dec; 292():163-171. PubMed ID: 30408555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The enhancement of siPLK1 penetration across BBB and its anti glioblastoma activity in vivo by magnet and transferrin co-modified nanoparticle.
    Liu DZ; Cheng Y; Cai RQ; Wang Bd WW; Cui H; Liu M; Zhang BL; Mei QB; Zhou SY
    Nanomedicine; 2018 Apr; 14(3):991-1003. PubMed ID: 29339188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC.
    Wang H; Tao Z; Feng M; Li X; Deng Z; Zhao G; Yin H; Pan T; Chen G; Feng Z; Li Y; Zhou Y
    Biochem Biophys Res Commun; 2020 Dec; 533(3):368-375. PubMed ID: 32962858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single siRNA Nanocapsules for Effective siRNA Brain Delivery and Glioblastoma Treatment.
    Zou Y; Sun X; Wang Y; Yan C; Liu Y; Li J; Zhang D; Zheng M; Chung RS; Shi B
    Adv Mater; 2020 Jun; 32(24):e2000416. PubMed ID: 32374446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
    Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
    Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles.
    Cohen ZR; Ramishetti S; Peshes-Yaloz N; Goldsmith M; Wohl A; Zibly Z; Peer D
    ACS Nano; 2015 Feb; 9(2):1581-91. PubMed ID: 25558928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
    Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
    Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
    Gerster K; Shi W; Ng B; Yue S; Ito E; Waldron J; Gilbert R; Liu FF
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):253-60. PubMed ID: 20394857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo.
    He S; Cen B; Liao L; Wang Z; Qin Y; Wu Z; Liao W; Zhang Z; Ji A
    Drug Deliv; 2017 Nov; 24(1):471-481. PubMed ID: 28181832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain-Targeted Cas12a Ribonucleoprotein Nanocapsules Enable Synergetic Gene Co-Editing Leading to Potent Inhibition of Orthotopic Glioblastoma.
    Ruan W; Xu S; An Y; Cui Y; Liu Y; Wang Y; Ismail M; Liu Y; Zheng M
    Adv Sci (Weinh); 2024 Sep; 11(33):e2402178. PubMed ID: 38943253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma.
    Michiue H; Eguchi A; Scadeng M; Dowdy SF
    Cancer Biol Ther; 2009 Dec; 8(23):2306-13. PubMed ID: 19901546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
    Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncoprotein Inhibitor Rigosertib Loaded in ApoE-Targeted Smart Polymersomes Reveals High Safety and Potency against Human Glioblastoma in Mice.
    Qin H; Jiang Y; Zhang J; Deng C; Zhong Z
    Mol Pharm; 2019 Aug; 16(8):3711-3719. PubMed ID: 31299161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
    McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
    Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ROS-Responsive Polymeric siRNA Nanomedicine Stabilized by Triple Interactions for the Robust Glioblastoma Combinational RNAi Therapy.
    Zheng M; Liu Y; Wang Y; Zhang D; Zou Y; Ruan W; Yin J; Tao W; Park JB; Shi B
    Adv Mater; 2019 Sep; 31(37):e1903277. PubMed ID: 31348581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. pH-responsive hybrid nanoparticle with enhanced dissociation characteristic for siRNA delivery.
    Shi M; Zhao X; Zhang J; Pan S; Yang C; Wei Y; Hu H; Qiao M; Chen D; Zhao X
    Int J Nanomedicine; 2018; 13():6885-6902. PubMed ID: 30498349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Charge Conversional Biomimetic Nanocomplexes as a Multifunctional Platform for Boosting Orthotopic Glioblastoma RNAi Therapy.
    Liu Y; Zou Y; Feng C; Lee A; Yin J; Chung R; Park JB; Rizos H; Tao W; Zheng M; Farokhzad OC; Shi B
    Nano Lett; 2020 Mar; 20(3):1637-1646. PubMed ID: 32013452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual sensitive and temporally controlled camptothecin prodrug liposomes codelivery of siRNA for high efficiency tumor therapy.
    Li Y; Liu R; Yang J; Ma G; Zhang Z; Zhang X
    Biomaterials; 2014 Dec; 35(36):9731-45. PubMed ID: 25189519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma.
    Pezuk JA; Brassesco MS; Morales AG; de Oliveira JC; de Paula Queiroz RG; Machado HR; Carlotti CG; Neder L; Scrideli CA; Tone LG
    Cancer Gene Ther; 2013 Sep; 20(9):499-506. PubMed ID: 23887645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients.
    Kolosenko I; Edsbäcker E; Björklund AC; Hamil AS; Goroshchuk O; Grandér D; Dowdy SF; Palm-Apergi C
    J Control Release; 2017 Sep; 261():199-206. PubMed ID: 28684168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.